Journal Mobile Options
Table of Contents
Vol. 38, No. 1-2, 2014
Issue release date: July 2014
Dement Geriatr Cogn Disord 2014;38:16-30
(DOI:10.1159/000355682)

Emergence of Mild Cognitive Impairment in Late Middle-Aged Adults in the Wisconsin Registry for Alzheimer's Prevention

Koscik R.L. · La Rue A. · Jonaitis E.M. · Okonkwo O.C. · Johnson S.C. · Bendlin B.B. · Hermann B.P. · Sager M.A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Aim: It is difficult to reliably detect the earliest signs of Alzheimer's disease (AD)-associated cognitive impairment. Our aim was to compare 3 psychometric methods of identifying amnestic mild cognitive impairment (aMCI) in a middle-aged longitudinal cohort enriched for AD risk. Methods: Wisconsin Registry for Alzheimer's Prevention (WRAP) participants with 3 waves of cognitive assessment over approximately 6 years were coded as meeting each of 3 psychometric aMCI definitions: (a) ‘aMCI standard-baseline' used published norms to establish cutoffs for baseline performance; (b) ‘aMCI robust-baseline' applied WRAP-specific robust norms to baseline, and (c) ‘aMCI robust-multiwave' applied these robust norms across 3 waves of assessment. Each group was compared to a cognitively healthy subset. Results: Half the aMCI standard-baseline and one third of the aMCI robust-baseline group reverted to normal ranges at follow-up. Only the aMCI robust-multiwave method had an aMCI × age interaction showing significantly worse age-related memory declines in the aMCI group compared to the cognitively healthy group over 6 years of follow-up. Conclusion: Both cross-sectional methods showed instability over time, with many reverting to normal performance after baseline. The multiwave approach identified a group who showed progressive memory declines over 3 visits. Being able to detect progressive decline in late middle age is a critical step in improving prevention efforts. © 2014 S. Karger AG, Basel



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Albert MS, Moss MB, Tanzii R, Jones K: Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc 2001;7:631-639.
  2. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ: Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 2005;19:520-531.
  3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinic characterization and outcome. Arch Neurol 1999;56:303-308.
  4. Winblad B, Palmer K, Kivipelto M, Jelic V, Gratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, et al: Mild cognitive impairment: beyond controversies, towards a consensus-report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246.
  5. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Peterson RC, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.
  6. Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Peterson RC, Weiner MW, et al: Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011;68:1526-1535.
  7. Debette S, Wolf PA, Beiser A, Au R, Himali JJ, Pikula A, Auerbach S, Decarli C, Seshadri S: Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology 2009;73:2071-2078.
  8. La Rue A, Hermann BP, Jones JE, Johnson S, Asthana S, Sager MA: Effect of parental family history of Alzheimer's disease on serial position profiles. Alzheimers Dement 2008;4:285-290.
  9. Chang TS, Coen MH, La Rue A, Jonaitis E, Koscik RL, Hermann B, Sager MA: Machine learning amplifies the effect of parental family history of Alzheimer's disease on list learning strategy. J Int Neuropsychol Soc 2012;18:428-439.
  10. Okonkwo O, Xu G, Dowling NM, Bendlin B, La Rue A, Hermann BP, Koscik R, Jonaitis E, Rowley H, Carlsson CM, et al: Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults. Neurology 2012;78:1769-1776.
  11. Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB: The preclinical phase of Alzheimer's disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol 2000;57:808-813.
  12. Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, Zonderman AB: Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology 2003;60:1089-1093.
  13. Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey Bloom J, Salmon DP, Delis DC: Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Psychiatry 2009;17:368-375.

    External Resources

  14. Ganguli M, Snitz BE, Saxton JA, Chang CC, Lee CW, Vander Bilt J, Hughes TF, Loewenstein DA, Unverzagt FW, Peterson RC: Outcomes of mild cognitive impairment by definition. Arch Neurol 2011;68:761-767.
  15. Anstey KJ, Cherbuin N, Christensen H, Burns R, Reglade-Meslin C, Salim A, Kumar R, Jorm AF, Sachdev P: Follow-up of mild cognitive impairment and related disorders over four years in adults in their sixties: the Path Through Life Study. Dement Geriatr Cogn Disord 2008;26:226-233.
  16. Schonknecht P, Pantel J, Kruse A, Schroder J: Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. Am J Psychiatry 2005;162:2071-2077.
  17. Dolcos S, MacDonald SW, Braslavsky A, Camicioli R, Dixon RA: Mild cognitive impairment is associated with selected functional markers: integrating concurrent, longitudinal, and stability effects. Neuropsychology 2012;26:209-223.
  18. Anstey KJ, Cherbuin N, Eramudugolla R, Sargent-Cox K, Easteal S, Kumar R, Sachdev P: Characterizing mild cognitive disorders in the young-old over 8 years: prevalence, estimated incidence, stability of diagnosis, and impact on IADLs. Alzheimers Dement 2013;9:640-648.
  19. Sager MA, Hermann BP, La Rue A: Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 2005;18:245-249.
  20. Schmidt M: Rey Auditory Verbal Learning Test: A Handbook. Los Angeles, Western Psychological Services, 1996.
  21. DeSanti S, Pirraglia E, Barr W, Babb J, Williams S, Rogers K, Glodzik L, Brys M, Mosconi L, Reisberg B, et al: Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline. Neuropsychology 2008;22:469-484.
  22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
  23. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
  24. Wechsler D: Wechsler Abbreviated Scale of Intelligence. San Antonio, The Psychological Corporation, 1999.
  25. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
  26. Radloff L: The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.

    External Resources

  27. Grice JW: Computing and evaluating factor scores. Psychol Methods 2001;6:430-450.
  28. Lezak M, Howieson D, Loring D: Neuropsychological Assessment, ed 4. New York, Oxford University Press, 2004.
  29. Wechsler D: Wechsler Adult Intelligence Scale. San Antonio, Psychological Corporation, 1997.
  30. Dowling NM, Hermann B, La Rue A, Sager MA: Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. Neuropsychology 2010;24:742-756.
  31. Jonaitis E, La Rue A, Mueller K, Koscik R, Hermann B, Sager MA: Cognitive activities and cognitive performance in middle-aged adults at risk for Alzheimer's disease. Psychol Aging, in press.
  32. Barona A, Reynolds CR, Chastain R: A demographically based index of premorbid intelligence for the WAIS-R. J Consult Clin Psychol 1984;52:885-887.

    External Resources

  33. Crawford JR, Stewart LE, Parker DM, Besson JAO, Cochrane RHB: Estimation of premorbid intelligence: combining psychometric and demographic approaches improves predictive accuracy. Pers Individ Diff 1989;10:793-796.
  34. Griffin SL, Mindt MR, Rankin EJ, Ritchie AJ, Scott JG: Estimating premorbid intelligence: comparison of traditional and contemporary methods across the intelligence continuum. Arch Clin Neuropsychol 2011;17:497-507.

    External Resources

  35. Duff K: Predicting premorbid memory functioning in older adults. Appl Neuropsychol 2010;17:278-282.
  36. Duff K, Chelune GJ, Dennett K: Predicting estimates of premorbid memory functioning: validation in a dementia sample. Arch Clin Neuropsychol 2011;26:701-705.
  37. Manly JJ, Jacobs DM, Touradji P, Small SA, Stern Y: Reading level attenuates differences in neuropsychological test performance between African American and White elders. J Int Neuropsychol Soc 2002;8:341-348.
  38. Carlozzi NE, Stout JC, Mills JA, Duff K, Beglinger LJ, Aylward EH, Whitlock KB, Solomon AC, Queller S, Langbehn DR, et al: Estimating premorbid IQ in the prodromal phase of a neurodegenerative disease. Clin Neuropsychol 2011;25:757-777.
  39. Wilkinson G: Wide Range Achievement Test - Revision 3. Wilmington, Jastak Association, 1993.
  40. Sliwinski MJ, Hofer SM, Hall C, Buschke H, Lipton RB: Modeling memory decline in older adults: the importance of preclinical dementia, attrition, and chronological age. Psychol Aging 2003;18:658-671.
  41. Tuokko H, Garrett DD, McDowell I, Silverberg N, Kristiansson B: Cognitive decline in high-functioning older adults: reserve or ascertainment bias? Aging Ment Health 2003;7:259-270.
  42. Bruscoli M, Lovestone S: Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004;16:129-140.
  43. Cherbuin N, Reglade-Meslin C, Kumar R, Jacomb P, Easteal S, Christensen H, Sachdev P, Anstey KJ: Risk factors of transition from normal cognition to mild cognitive disorder: the Path Through Life Study. Dement Geriatr Cogn Disord 2009;28:47-55.
  44. Willett J, Singer J, Martin N: The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations. Dev Psychopathol 1998;10:395-426.
  45. Aiken LS, West SG: Multiple Regression: Testing and Interpreting Interactions. London, Sage Publications, 1991.
  46. Palmer K, Backman L, Winblad B, Fratiglioni L: Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. Am J Geriatr Psychiatry 2008;16:603-611.
  47. Collie A, Maruff P, Currie J: Behavioral characterization of mild cognitive impairment. J Clin Exp Neuropsychol 2002;24:720-733.
  48. Brooks BL, Iverson GL, White T: Substantial risk of ‘accidental MCI' in healthy older adults: base rates of low memory scores in neuropsychological assessment. J Int Neuropsychol Soc 2007;13:490-500.
  49. Palmer BW, Boone KB, Lesser IM, Wohl MA: Base rates of ‘impaired' neuropsychological test performance among healthy older adults. Arch Clin Neuropsychol 1998;13:503-511.
  50. Murayama N, Tagaya H, Ota K, Fujishiro H, Manabe Y, Sato K, Isek E: Neuropsychological detection of the early stage of amnestic mild cognitive impairment without objective memory impairment. Dement Geriatr Cogn Disord 2013;35:98-105.
  51. Donix M, Burggren AC, Suthana NA, Siddarth P, Ekstrom AD, Krupa AK, Jones M, Martin-Harris L, Ercoli LM, Miller KJ, et al: Family history of Alzheimer's disease and hippocampal structure in healthy people. Am J Psychiatry 2010;167:1399-1406.
  52. Xiong C, Roe CM, Buckles V, Fagan A, Holtzman DM, Balota D, Duchek J, Storandt M, Mintun M, Grant E, et al: Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch Neurol 2011;68:1311-1317.
  53. Johnson SC, Schmitz TW, Trivedi MA, Ries ML, Torgerson BM, Carlsson CM, Asthana S, Hermann BP, Sager MA: The influence of Alzheimer disease family history and apolipoprotein E epsilon 4 on mesial temporal lobe activation. J Neurosci 2006;26:6069-6076.
  54. Wisdom NM, Callahan JL, Hawkins KA: The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol Aging 2011;32:63-74.
  55. Stein J, Luppa M, Maier W, Tebarth F, Heser K, Scherer M, Zimmermann T, Eisele M, Bickel H, Mosch E, et al: The assessment of changes in cognitive functioning in the elderly: age- and education-specific reliable change indices for the SIDAM. Dement Geriatr Cogn Disord 2012;33:73-83.
  56. Duff K, Beglinger LJ, Van Der Heiden S, Moser DJ, Arndt S, Schultz SK, Paulsen JS: Short-term practice effects in amnestic mild cognitive impairment: implications for diagnosis and treatment. Int Psychogeriatr 2008;20:986-999.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50